Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
0.3891
+0.0145 (3.87%)
At close: Sep 22, 2026, 4:00 PM EDT
0.3890
-0.0001 (-0.03%)
After-hours: Sep 22, 2026, 7:30 PM EDT
Context Therapeutics Employees
Context Therapeutics had 15 employees as of December 31, 2025. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$3,063,856
Market Cap
35.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 3 | 25.00% |
| Dec 31, 2024 | 12 | 7 | 140.00% |
| Dec 31, 2023 | 5 | -4 | -44.44% |
| Dec 31, 2022 | 9 | - | - |
| Jun 30, 2021 | 2 | - | - |
| Mar 31, 2021 | 2 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Aligos Therapeutics | 82 |
| aTyr Pharma | 60 |
| BeyondSpring | 44 |
| Quince Therapeutics | 38 |
| Filana Therapeutics | 20 |
| ABVC BioPharma | 19 |
| BriaCell Therapeutics | 16 |
CNTX News
- 13 days ago - Context Therapeutics doses first patient in CT-202 trial - TheFly
- 13 days ago - Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 - GlobeNewsWire
- 6 weeks ago - Context downgraded to Market Perform from Outperform at LifeSci Capital - TheFly
- 6 weeks ago - Context Therapeutics price target lowered to $3 from $4 at Citizens - TheFly
- 6 weeks ago - Context Therapeutics reports Q2 EPS (15c), consensus (9c) - TheFly
- 6 weeks ago - Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - GlobeNewsWire
- 6 weeks ago - Context Therapeutics Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Context Therapeutics Earnings release: Q2 2026 - Filings